23
May

Strata Oncology, Inc., a precision oncology company, today announced the launch of its 2.0 test, StrataNGS, a custom-designed, 90-gene targeted assay focused on actionable genetic alterations in tumor tissue, including standard of care markers and clinical trial eligibility markers.

Link

Comments are closed.